Corcept Therapeutics
CORT
156 hedge funds and large institutions have $824M invested in Corcept Therapeutics in 2017 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 38 reducing their positions, and 13 closing their positions.
276% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $676K
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
79% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 38
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
24% more capital invested
Capital invested by funds: $665M → $824M (+$159M)
16% more funds holding
Funds holding: 135 → 156 (+21)
8% more ownership
Funds ownership: 53.69% → 61.7% (+8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$12.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$11.6M |
| 3 |
Renaissance Technologies
New York
|
+$8.97M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.5M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$6.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
-$5.76M |
| 2 |
Morgan Stanley
New York
|
-$5.61M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.51M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.39M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.82M |
CORT Hedge Fund Activity: Q2 2017 in Review
156 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2017, worth a combined $824M — up 24% from $665M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CORT positions and 13 closed out — a net gain of 21 holders — while 68 added to existing stakes and 38 trimmed.
The largest buyer was Marshall Wace North America, opening a new position worth an estimated $12.6M. The largest seller was Ingalls & Snyder LLC, cutting an estimated $5.76M.
- 156 institutional investors held Corcept Therapeutics (CORT) as of Q2 2017, up from 135 in Q1 2017.
- Funds reported $824M of Corcept Therapeutics stock for Q2 2017, up 24% quarter-over-quarter.
- 34 funds opened new Corcept Therapeutics positions in Q2 2017 and 13 closed out, a net change of +21 holders.
- The largest Corcept Therapeutics buyer in Q2 2017 was Marshall Wace North America, an estimated $12.6M added.
- The largest Corcept Therapeutics seller in Q2 2017 was Ingalls & Snyder LLC, an estimated $5.76M sold.
Based on aggregated 13F filings for Q2 2017.